Sanofi Deferred Long Term Liab from 2010 to 2024

SNY Stock  USD 49.46  0.57  1.14%   
Sanofi ADR Deferred Long Term Liabilities yearly trend continues to be fairly stable with very little volatility. Deferred Long Term Liabilities will likely drop to about 4 B in 2024. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2013-12-31
Previous Quarter
7.3 B
Current Value
6.2 B
Quarterly Volatility
2.9 B
 
Yuan Drop
 
Covid
Check Sanofi ADR financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanofi main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 B, Interest Expense of 1.1 B or Selling General Administrative of 11.2 B, as well as many exotic indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0228 or PTB Ratio of 1.44. Sanofi financial statements analysis is a perfect complement when working with Sanofi ADR Valuation or Volatility modules.
  
This module can also supplement Sanofi ADR's financial leverage analysis and stock options assessment as well as various Sanofi ADR Technical models . Check out the analysis of Sanofi ADR Correlation against competitors.
For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

Latest Sanofi ADR's Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of Sanofi ADR over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Sanofi ADR's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sanofi ADR's overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

Sanofi Deferred Long Term Liab Regression Statistics

Arithmetic Mean3,589,112,712
Geometric Mean3,026,109,785
Coefficient Of Variation61.84
Mean Deviation1,926,711,749
Median2,334,000,000
Standard Deviation2,219,602,520
Sample Variance4926635.3T
Range6.4B
R-Value0.75
Mean Square Error2348478.5T
R-Squared0.56
Significance0
Slope370,533,760
Total Sum of Squares68972894.8T

Sanofi Deferred Long Term Liab History

2024B
20237.2 B
20226.2 B
20217.7 B
20206.1 B
20192.3 B
20184.7 B

About Sanofi ADR Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Sanofi ADR income statement, its balance sheet, and the statement of cash flows. Sanofi ADR investors use historical funamental indicators, such as Sanofi ADR's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Sanofi ADR investors may use each financial statement separately, they are all related. The changes in Sanofi ADR's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sanofi ADR's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Sanofi ADR Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Sanofi ADR. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Deferred Long Term Liabilities7.2 BB

Currently Active Assets on Macroaxis

When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:
Check out the analysis of Sanofi ADR Correlation against competitors.
For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Sanofi Stock analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.43)
Earnings Share
1.94
Revenue Per Share
18.492
Quarterly Revenue Growth
0.023
Return On Assets
0.0454
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.